US 12,257,257 B2
Testosterone dodecanoate compositions and methods
Mahesh V. Patel, Salt Lake City, UT (US); Kongnara Papangkorn, Salt Lake City, UT (US); Jonathan Ogle, Salt Lake City, UT (US); Nachiappan Chidambaram, Salt Lake City, UT (US); and Benjamin J. Bruno, Salt Lake City, UT (US)
Filed by Lipocine, Inc., Salt Lake City, UT (US)
Filed on May 3, 2024, as Appl. No. 18/654,926.
Claims priority of provisional application 63/516,015, filed on Jul. 27, 2023.
Prior Publication US 2025/0032507 A1, Jan. 30, 2025
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/568 (2013.01) [A61K 9/0053 (2013.01)] 30 Claims
 
1. A method of treating a condition in a subject, said method comprising orally administering a pharmaceutical substance to said subject, wherein said pharmaceutical substance comprises or is prepared from a TDPC and wherein in comparison to at least one of a TDPC pre-administration state of said subject and a placebo administration, said administration results in at least one of:
no deterioration in said subject of at least one of cardiovascular risk, cardiovascular health, prostate health, muscle health, CNS health, GI health, cell health, and median hospitalization duration, and
an improvement in said subject of at least one of cardiovascular risk, cardiovascular health, prostate health, muscle health, CNS health, GI health, cell health, and median hospitalization duration.